To rapidly screen the 50 selected compounds for their ability to inhibit NAPRT, we used their capacity to sensitize the NAPRT-proficient ovarian cancer cell line, OVCAR-5, to FK866 as a reading frame (since this cell line is normally resistant to the NAMPT inhibitor but becomes sensitized to it through either NAPRT silencing or inhibition). This evidence concerns the gene NAMPT and ovarian carcinoma.